Get the Stockscreener App
11.43
2.39%
-0.28
After Hours:
11.24
-0.19
-1.66%
Cartesian Therapeutics Inc stock is traded at $11.43, with a volume of 23,116.
It is down -2.39% in the last 24 hours and down -12.48% over the past month.
Cartesian Therapeutics Inc is a clinical-stage biopharmaceutical company. The company uses its ImmTOR immune tolerance platform, which is designed to give rise to antigen-specific immunity, mitigating unwanted immune responses. The company leverages its proprietary technology and manufacturing platform to introduce one or more mRNA molecules into cells to enhance their function.
See More
Previous Close:
$11.71
Open:
$11.55
24h Volume:
23,116
Relative Volume:
0.35
Market Cap:
$297.20M
Revenue:
$26.00M
Net Income/Loss:
$-219.71M
P/E Ratio:
-0.2295
EPS:
-49.8
Net Cash Flow:
$-51.37M
1W Performance:
+8.44%
1M Performance:
-12.48%
6M Performance:
-41.89%
1Y Performance:
-12.61%
1-Day Range:
$11.30
$11.71
1-Week Range:
$10.13
$12.25
52-Week Range:
$8.46
$26.50
Cartesian Therapeutics Inc Stock (RNAC) Company Profile
Name
Cartesian Therapeutics Inc
Sector
Industry
Phone
301-348-8698
Address
7495 NEW HORIZON WAY, FREDERICK
Compare RNAC with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RNAC
Cartesian Therapeutics Inc
|
11.43 | 304.48M | 26.00M | -219.71M | -51.37M | -49.80 |
|
VRTX
Vertex Pharmaceuticals Inc
|
390.30 | 101.51B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
565.97 | 59.52B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
442.73 | 56.69B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
652.43 | 39.57B | 3.06B | 1.28B | -614.78M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
309.69 | 36.56B | 3.81B | -644.79M | -669.77M | -6.24 |
Cartesian Therapeutics Inc Stock (RNAC) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-09-25 | Initiated | Wedbush | Outperform |
| Dec-19-24 | Initiated | BTIG Research | Buy |
| Aug-06-24 | Initiated | TD Cowen | Buy |
| Jul-02-24 | Downgrade | Oppenheimer | Outperform → Perform |
| Jun-04-24 | Initiated | Oppenheimer | Outperform |
| May-24-24 | Initiated | Mizuho | Buy |
| Apr-23-24 | Reiterated | H.C. Wainwright | Buy |
| Apr-23-24 | Initiated | Leerink Partners | Outperform |
| Aug-18-23 | Downgrade | SVB Securities | Outperform → Market Perform |
| Jun-14-22 | Reiterated | Needham | Buy |
| Jun-06-22 | Initiated | SVB Leerink | Outperform |
| Jun-15-21 | Initiated | BTIG Research | Buy |
| Jan-26-21 | Upgrade | Mizuho | Neutral → Buy |
| Oct-01-20 | Downgrade | Mizuho | Buy → Neutral |
| Oct-01-20 | Downgrade | William Blair | Outperform → Mkt Perform |
| Jun-12-20 | Downgrade | Stifel | Buy → Hold |
| Apr-28-20 | Initiated | H.C. Wainwright | Buy |
| Jan-29-20 | Initiated | Cantor Fitzgerald | Overweight |
| Jan-21-20 | Initiated | William Blair | Outperform |
| Jun-27-18 | Initiated | Janney | Buy |
| Mar-30-17 | Reiterated | UBS | Buy |
View All
Cartesian Therapeutics Inc Stock (RNAC) Latest News
Measuring Cartesian Therapeutics Inc.’s beta against major indicesJuly 2025 Recap & Verified Chart Pattern Trade Signals - Newser
What makes Cartesian Therapeutics Inc. stock price move sharplyInsider Selling & AI Enhanced Trading Alerts - Newser
How Cartesian Therapeutics Inc. stock performs during market volatilityEarnings Overview Summary & Momentum Based Trading Signals - Newser
Can Cartesian Therapeutics Inc. continue delivering strong returnsPost Earnings Surprise Movers - thegnnews.com
Real time alert setup for Cartesian Therapeutics Inc. performanceProfit Target Planning with Exit Confidence - Newser
Cartesian Therapeutics Reports Positive Q2 2025 Earnings - TipRanks
Cartesian Therapeutics Inc. stock trend forecastWeekly Chart-Based Forecast for Traders - Newser
Relative strength of Cartesian Therapeutics Inc. in sector analysisFree Market Momentum and Signal Alerts - Newser
Why Cartesian Therapeutics Inc. stock attracts strong analyst attentionSafe Entry Screening with Data Backed Analysis - Newser
Multi factor analysis applied to Cartesian Therapeutics Inc.Free AI Based High Gain Watchlist Scanner - Newser
Cartesian Therapeutics Second Quarter 2025 Earnings: EPS Beats Expectations, Revenues Lag - Yahoo Finance
Cartesian Therapeutics 2025 Q2 Earnings Strong Net Income Amid Revenue Decline - AInvest
Cartesian Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update - GlobeNewswire
Cartesian Therapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Cartesian (RNAC) Q2 Revenue Drops 99% - sharewise.com
Cartesian Therapeutics reports second quarter 2025 financial results and provides business update - MarketScreener
Cartesian Therapeutics Inc Reports Q2 2025 EPS of $0.51, Surpassing Estimates, with Revenue at $298,000 - GuruFocus
Cartesian Therapeutics, Inc. SEC 10-Q Report - TradingView
Cartesian Therapeutics (RNAC) to Release Quarterly Earnings on Thursday - Defense World
Bank of New York Mellon Corp Boosts Stock Holdings in Cartesian Therapeutics, Inc. (NASDAQ:RNAC) - Defense World
Cartesian Therapeutics, Inc. (NASDAQ:RNAC) Receives $40.00 Average Target Price from Analysts - Defense World
Design Therapeutics, Inc. shares rise 1.26% intraday as Cartesian Therapeutics reports strong clinical trial progress and global expansion. - AInvest
Cartesian Therapeutics Announces New Employment Inducement Grants - The Globe and Mail
Cartesian Therapeutics Grants Inducement Awards to New Employees. - AInvest
Cartesian Therapeutics Announces New Employee Incentive Grants - AInvest
Zacks.com featured highlights Amazon.com, Alphabet and Meta Platforms - The Globe and Mail
Candlestick Signal Suggests Reversal in Cartesian Therapeutics Inc.Expert Verified Stock Trade Ideas Backed by Data - metal.it
Cartesian Therapeutics Inc. Stock Analysis and ForecastBuild wealth faster with disciplined trading - Jammu Links News
Does Cartesian Therapeutics Inc. stock perform well during market downturnsMaximize returns with smart investment plans - Jammu Links News
What institutional investors are buying Cartesian Therapeutics Inc. stockUnlock powerful investment tools for free - Jammu Links News
What catalysts could drive Cartesian Therapeutics Inc. stock higher in 2025Get timely alerts on top-performing stocks - Jammu Links News
When is Cartesian Therapeutics Inc. stock expected to show significant growthCapitalize on market shifts before others do - Jammu Links News
Is Cartesian Therapeutics Inc. stock overvalued or undervaluedExceptional trading results - Jammu Links News
Can momentum traders help lift Cartesian Therapeutics Inc.Predictive Short-Term Market Reversal Alerts - Newser
What are the technical indicators suggesting about Cartesian Therapeutics Inc.Free Stock Forecasts For 2025 - Jammu Links News
Chart overlay techniques for tracking Cartesian Therapeutics Inc.Free Alert Feed for Momentum Based Picks - Newser
How to integrate Cartesian Therapeutics Inc. into portfolio analysis toolsRisk-Managed Trade Alerts for Consistency - Newser
Price action breakdown for Cartesian Therapeutics Inc.Free Fast Entry High Potential Stock Alerts - Newser
Progressive Investment Management Corp Reduces Amazon Holdings - The Globe and Mail
How many analysts rate Cartesian Therapeutics Inc. as a “Buy”Free Stock Target Finder With Proven Results - Jammu Links News
Technical signs of recovery in Cartesian Therapeutics Inc.Fast Return Equity Forecast With Logic - Newser
Myasthenia Gravis Market Growth to Accelerate in Forecast - openPR.com
Cartesian Therapeutics Inc. Moves Into Overbought Range Analysts CautiousBuy Alerts With Low Risk Confirmation Noted - metal.it
How to use a screener to detect Cartesian Therapeutics Inc. breakoutsPortfolio Building Plan and Summary Guide - Newser
New Product Launches: Will They Boost Cartesian Therapeutics Inc. Stock in 2025Entry and Exit Strategy Optimizer Tool Tested - metal.it
Cartesian Therapeutics Inc Stock (RNAC) Financials Data
Revenue
Net Income
Cash Flow
EPS
Cartesian Therapeutics Inc Stock (RNAC) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| English Emily | Chief Operations Officer |
Apr 15 '25 |
Option Exercise |
3.30 |
7,500 |
24,750 |
47,726 |
| SPRINGER TIMOTHY A | Director |
Apr 10 '25 |
Buy |
10.47 |
48,595 |
508,751 |
620,175 |
| SPRINGER TIMOTHY A | Director |
Apr 09 '25 |
Buy |
9.43 |
41,782 |
393,947 |
571,580 |
| SPRINGER TIMOTHY A | Director |
Apr 11 '25 |
Buy |
10.77 |
36,338 |
391,455 |
656,513 |
| SPRINGER TIMOTHY A | Director |
Apr 10 '25 |
Buy |
10.47 |
8,575 |
89,773 |
8,637,273 |
| SPRINGER TIMOTHY A | Director |
Apr 09 '25 |
Buy |
9.43 |
7,373 |
69,517 |
8,628,698 |
| SPRINGER TIMOTHY A | Director |
Apr 11 '25 |
Buy |
10.77 |
6,412 |
69,074 |
8,643,685 |
| SPRINGER TIMOTHY A | Director |
Mar 20 '25 |
Buy |
15.59 |
54,889 |
855,593 |
8,621,325 |
| SPRINGER TIMOTHY A | Director |
Mar 19 '25 |
Buy |
14.97 |
20,234 |
302,962 |
8,566,436 |
| SPRINGER TIMOTHY A | Director |
Mar 18 '25 |
Buy |
14.42 |
14,740 |
212,599 |
8,546,202 |
0.11%
1.56%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):